Interclean Shanghai

Ziosoft receives FDA Clearance for CT Cardiac function analysis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Ziosoft, Inc., a leader in advanced visualization and analysis software for medical imaging, announced that it has received 510(k) clearance from the U.S FDA approval to market two additional applications for use with the Ziostation thin-client system.

These applications enhance the productivity and diagnostic capability of physicians when evaluating patients' heart health. Both the cardiac function analysis and calcium scoring applications can be accessed throughout the enterprise on the Ziostation thin-client system to provide physicians with improved efficiency and real-time collaboration when assessing results from a CT cardiac scan.

According to the National Center for Health Statistics (NCHS) every year since 1900, except 1918, cardiovascular disease accounted for more deaths than any other single cause or group of causes of death in the United States. Nearly 2,400 Americans die of cardiovascular disease each day, an average of one death every 37 seconds. These new applications from Ziosoft will contribute to more efficient interpretation and improved communication of test results, leading to enhanced quality of care for patients.

Kazuhiko Matsumoto, Ziosoft's chief executive officer, We are proud of our long history of developing software applications which aid physicians in evaluating diseases. These latest applications will be added to Ziosoft's suite of applications for a robust cardiac tool set for the market.

 

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »